Here are four things to know.
1. The company reported $5.944 billion in worldwide sales for the third quarter, an 18.4 percent year-over-year increase.
2. AbbVie’s Viekira global sales for the quarter were $469 million. The HCV drug is now approved in 61 countries.
3. The company’s net interest expense for the quarter was $197 million.
4. AbbVie’s diluted earnings per share for the third quarter were $1.31, up approximately 27 percent.
More articles on gastroenterology:
Lovelace Medical Group adds Dr. Julie Farrer: 3 things to know
Global endoscopy market to reach $9.7B by 2021: 5 key trends
The biggest challenges for GI in 2016: 3 gastroenterologists weigh in
